SG11201407340YA - Treatment of myelosuppression - Google Patents
Treatment of myelosuppressionInfo
- Publication number
- SG11201407340YA SG11201407340YA SG11201407340YA SG11201407340YA SG11201407340YA SG 11201407340Y A SG11201407340Y A SG 11201407340YA SG 11201407340Y A SG11201407340Y A SG 11201407340YA SG 11201407340Y A SG11201407340Y A SG 11201407340YA SG 11201407340Y A SG11201407340Y A SG 11201407340YA
- Authority
- SG
- Singapore
- Prior art keywords
- patient
- day
- cycle
- international
- control arm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/169355 A1 (51) International Patent Classification: A61K 31/727 (2006.01) C08B 37/10 (2006.01) A61K31/715 (2006.01) (21) International Application Number: PCT/US2013/031053 13 March 2013 (13.03.2013) English English (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/644,623 61/644,556 61/648,043 61/653,362 61/664,611 61/668,709 61/678,053 61/702,207 61/724,836 1792 Bell Tower Lane, Weston, FL 33326 (US). (72) Inventor: MARCUS, Stephen; Suite 222, 1792 Bell Tower Lane, Weston, FL 33326 (US). 9 May 2012 (09.05.2012) US 9 May 2012 (09.05.2012) us 16 May 2012 (16.05.2012) us 30 May 2012 (30.05.2012) us 26 June 2012 (26.06.2012) us 6 July 2012 (06.07.2012) us 31 July 2012 (31.07.2012) us 17 September 2012 (17.09.2012) us 9 November 2012 (09.11.2012) us PARINGENIX, INC. [US/US]; Suite 222, (74) Agents: BECKER, Daniel et al.; Dechert LLP, P.O. Box 390460, Mountain View, CA 94039 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: TREATMENT OF MYELOSUPPRESSION FIG. 13A Platelet count 10 /nl (X 3 blood) o\ Control Arm Patients ODSH Arm Patients ~Z3C 231- Patient 6008 Patient 9003 Patient 1X002 Patient 14005 Patient 14003 Patient 9004 Patient 6009 Patient 14002 Patient 14001 Patient 9002 • Cycle 1 Day 1 • Cycle 1 Day 15 Cycle 1 Day 1 Cycle 1 Day 15 Control Arm Median 194 92 Control Arm Mean 193 88 Cycle 1 Day 1 Cycle 1 Day 15 ODSH Arm Median 194 199 ODSH Arm Mean 219 177 T-H o CJ (57) Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoies- is and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644556P | 2012-05-09 | 2012-05-09 | |
| US201261644623P | 2012-05-09 | 2012-05-09 | |
| US201261648043P | 2012-05-16 | 2012-05-16 | |
| US201261653362P | 2012-05-30 | 2012-05-30 | |
| US201261664611P | 2012-06-26 | 2012-06-26 | |
| US201261668709P | 2012-07-06 | 2012-07-06 | |
| US201261678053P | 2012-07-31 | 2012-07-31 | |
| US201261702207P | 2012-09-17 | 2012-09-17 | |
| US201261724836P | 2012-11-09 | 2012-11-09 | |
| PCT/US2013/031053 WO2013169355A1 (en) | 2012-05-09 | 2013-03-13 | Treatment of myelosuppression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407340YA true SG11201407340YA (en) | 2014-12-30 |
Family
ID=49549076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914117QA SG10201914117QA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
| SG11201407340YA SG11201407340YA (en) | 2012-05-09 | 2013-03-13 | Treatment of myelosuppression |
| SG10201603059YA SG10201603059YA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914117QA SG10201914117QA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201603059YA SG10201603059YA (en) | 2012-05-09 | 2013-03-13 | Treatment Of Myelosuppression |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US9271999B2 (en) |
| EP (2) | EP3785720A1 (en) |
| JP (3) | JP6177885B2 (en) |
| KR (2) | KR102165348B1 (en) |
| CN (3) | CN104411316B (en) |
| AU (1) | AU2013260101B2 (en) |
| BR (1) | BR112014028094B1 (en) |
| CA (2) | CA3122808A1 (en) |
| CL (2) | CL2014003017A1 (en) |
| DK (1) | DK2846809T3 (en) |
| EA (1) | EA029382B1 (en) |
| ES (1) | ES2848050T3 (en) |
| HK (1) | HK1207574A1 (en) |
| HU (1) | HUE053247T2 (en) |
| IL (1) | IL235593B (en) |
| LT (1) | LT2846809T (en) |
| MX (2) | MX370567B (en) |
| PL (1) | PL2846809T3 (en) |
| PT (1) | PT2846809T (en) |
| SG (3) | SG10201914117QA (en) |
| WO (1) | WO2013169355A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013260101B2 (en) | 2012-05-09 | 2016-10-27 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| JP2016534057A (en) * | 2013-10-22 | 2016-11-04 | カンテックス ファーマシューティカルズ， インコーポレイテッド | Methods for treating and preventing radiation injury |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| EP3265090A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating cancer associated with a ras mutation |
| PE20180528A1 (en) | 2015-07-13 | 2018-03-19 | Beyondspring Pharmaceuticals Inc | PLINABULIN COMPOSITIONS |
| MX2018009413A (en) | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs. |
| KR20240091084A (en) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| CN107569486A (en) * | 2017-08-23 | 2018-01-12 | 北京京佑奇康生物科技有限公司 | Menglusitena treats the new application of thrombopenia |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CA3089226A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| AU2020210869A1 (en) * | 2019-01-25 | 2021-08-19 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
| JP2022529476A (en) | 2019-04-17 | 2022-06-22 | コンパス パスファインダー リミテッド | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| WO2021041532A1 (en) * | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| TW202128617A (en) * | 2019-11-13 | 2021-08-01 | 日商大鵬藥品工業股份有限公司 | Novel salt of terphenyl compound |
| WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
| EP4182452A4 (en) | 2020-07-14 | 2024-07-31 | Optimvia Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| KR20230058289A (en) | 2021-10-21 | 2023-05-03 | 숙명여자대학교산학협력단 | Combination therapy with griseofulvin for blood cancer |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2374910A1 (en) | 1976-10-23 | 1978-07-21 | Choay Sa | PREPARATION BASED ON HEPARIN, INCLUDING LIPOSOMES, PROCESS FOR OBTAINING IT AND MEDICINAL PRODUCTS CONTAINING SUCH PREPARATIONS |
| US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
| FR2553287B1 (en) | 1983-10-18 | 1986-09-12 | Choay Sa | COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS |
| DE3422518A1 (en) | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
| FR2584606A1 (en) | 1985-07-12 | 1987-01-16 | Dropic | USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE |
| US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
| IT1234826B (en) | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| AU7681091A (en) | 1990-04-05 | 1991-10-30 | John R Hoidal | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases |
| US5250519A (en) | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
| IT1254216B (en) | 1992-02-25 | 1995-09-14 | Opocrin Spa | POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| AU3938093A (en) | 1992-04-02 | 1993-11-08 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
| US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5306724A (en) | 1992-08-17 | 1994-04-26 | Clintec Nutrition Company | Method for preventing and treating atherosclerosis |
| GB2270841A (en) | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
| US5296471A (en) | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| WO1994018989A1 (en) | 1993-02-22 | 1994-09-01 | Cavalier Pharmaceuticals, Inc. | Use of heparin to inhibit interleukin-8 |
| SE9302135D0 (en) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | NEW PHARMACEUTICAL COMPOSITION |
| US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
| US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
| WO1995030424A1 (en) | 1994-05-06 | 1995-11-16 | Glycomed Incorporated | O-desulfated heparin derivatives, methods of making and uses thereof |
| US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| CA2261872C (en) | 1996-07-29 | 2004-06-15 | Thomas P. Kennedy | Methods of treating asthma with o-desulfated heparin |
| US6154502A (en) | 1996-08-22 | 2000-11-28 | Intel Corporation | Signal constellation slicer |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| CA2281224A1 (en) | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
| DE69821932T2 (en) | 1997-05-30 | 2004-12-16 | Arch Development Corp., Chicago | P-SELECTIN TRANSLOCATION INTO VASCULAR EPITHELIAL LUMEN BY IONIZING RADIATION |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| IL142255A0 (en) | 1998-11-13 | 2002-03-10 | Lilly Co Eli | Method of treating heparin-induced thrombocytopenia |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US6514502B1 (en) | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
| EP1223948A2 (en) | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| US20050026811A1 (en) | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| SI1385498T1 (en) * | 2001-04-18 | 2008-04-30 | Prometic Biosciences Inc | Fatty acids as neutrophil survival and activation factors. |
| EP1542704A1 (en) | 2002-04-18 | 2005-06-22 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
| WO2004004702A2 (en) | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US20080207895A1 (en) | 2002-11-27 | 2008-08-28 | Rosenberg Robert D | Methods for synthesizing polysaccharides |
| US20040180812A1 (en) * | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
| WO2005089365A2 (en) | 2004-03-16 | 2005-09-29 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
| JP4972545B2 (en) * | 2004-04-22 | 2012-07-11 | セレーター ファーマスーティカルズ、インク． | Liposomal preparations of anthracyclines and cytidine analogs |
| US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
| US7468358B2 (en) * | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
| JP2006076968A (en) | 2004-09-10 | 2006-03-23 | Seikagaku Kogyo Co Ltd | Physiologically active molecule-containing crosslinked heparin gel composition |
| CA2616166A1 (en) | 2005-07-22 | 2007-02-01 | The Regents Of The University Of California | Heparin compositions and selectin inhibition |
| WO2007019554A2 (en) | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
| EP1939278A4 (en) | 2005-09-30 | 2009-06-03 | Takara Bio Inc | Method for production of t cell population |
| CA2631891A1 (en) | 2005-12-16 | 2007-06-21 | Dnp Canada Inc. | Chitin derivatives for hyperlipidemia |
| WO2007115372A1 (en) | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
| US20100003226A1 (en) | 2006-07-26 | 2010-01-07 | Intrexon Corporation | Methods and Compositions for Treating Disease |
| JP2010504356A (en) | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | Combination therapy of cancer and infectious diseases using anti-B7-H1 antibody |
| CA2678587A1 (en) | 2007-02-28 | 2008-09-04 | Paringenix, Inc. | O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| EP2170354A1 (en) | 2007-07-23 | 2010-04-07 | University of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009117677A2 (en) | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
| AU2009231634B2 (en) | 2008-04-04 | 2014-05-15 | University Of Utah Research Foundation | Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
| US8476249B2 (en) * | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
| US20130034534A1 (en) | 2009-09-29 | 2013-02-07 | Philipp Kroneberg | Method for treatment of patients with cystic fibrosis |
| CN102917711A (en) | 2010-03-12 | 2013-02-06 | 澳大利亚国立大学 | Heparan sulfate replacement therapy |
| KR101570404B1 (en) * | 2010-03-24 | 2015-11-20 | 르 라보레또레 쎄르비에르 | Prophylaxis of colorectal and gastrointestinal cancer |
| EP2588119A4 (en) | 2010-06-28 | 2014-01-08 | Stemtech Internat Inc | Methods and compositions for enhancing stem cell mobilization |
| CA2825152A1 (en) * | 2011-01-31 | 2012-08-09 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
| WO2012106379A1 (en) * | 2011-02-01 | 2012-08-09 | Paringenix, Inc. | Sensitization of cancer cells to treatment |
| WO2013016181A1 (en) | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
| WO2013166163A1 (en) | 2012-05-01 | 2013-11-07 | Duke University | Compositions and methods for heparan sulfate as a biomarker for transplant rejection |
| AU2013260101B2 (en) | 2012-05-09 | 2016-10-27 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| CN105431521A (en) | 2013-02-28 | 2016-03-23 | 哈佛学院校长同事会 | Methods and compositions for mobilizing stem cells |
| JP2016534057A (en) | 2013-10-22 | 2016-11-04 | カンテックス ファーマシューティカルズ， インコーポレイテッド | Methods for treating and preventing radiation injury |
| US20160296552A1 (en) | 2013-10-24 | 2016-10-13 | Cantex Pharmaceuticals, Inc. | Treating Bacterial Infections of the Lung |
| WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| US20160243168A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Adoptive cell transfer methods |
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| US20170106011A1 (en) | 2015-10-20 | 2017-04-20 | Cantex Pharmaceuticals, Inc. | Methods of treating traumatic brain injury and sequelae |
| WO2017123549A1 (en) | 2016-01-11 | 2017-07-20 | Cantex Pharmaceuticals, Inc. | Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids |
-
2013
- 2013-03-13 AU AU2013260101A patent/AU2013260101B2/en not_active Ceased
- 2013-03-13 KR KR1020147034512A patent/KR102165348B1/en active IP Right Grant
- 2013-03-13 CN CN201380036055.1A patent/CN104411316B/en not_active Expired - Fee Related
- 2013-03-13 CN CN202110756600.0A patent/CN113521093A/en active Pending
- 2013-03-13 CA CA3122808A patent/CA3122808A1/en not_active Abandoned
- 2013-03-13 BR BR112014028094-0A patent/BR112014028094B1/en not_active IP Right Cessation
- 2013-03-13 EP EP20189050.6A patent/EP3785720A1/en not_active Withdrawn
- 2013-03-13 CA CA2872855A patent/CA2872855C/en active Active
- 2013-03-13 DK DK13787651.2T patent/DK2846809T3/en active
- 2013-03-13 JP JP2015511452A patent/JP6177885B2/en not_active Expired - Fee Related
- 2013-03-13 ES ES13787651T patent/ES2848050T3/en active Active
- 2013-03-13 US US13/801,990 patent/US9271999B2/en not_active Expired - Fee Related
- 2013-03-13 HU HUE13787651A patent/HUE053247T2/en unknown
- 2013-03-13 KR KR1020207028539A patent/KR102452803B1/en active IP Right Grant
- 2013-03-13 PL PL13787651T patent/PL2846809T3/en unknown
- 2013-03-13 SG SG10201914117QA patent/SG10201914117QA/en unknown
- 2013-03-13 SG SG11201407340YA patent/SG11201407340YA/en unknown
- 2013-03-13 PT PT137876512T patent/PT2846809T/en unknown
- 2013-03-13 EP EP13787651.2A patent/EP2846809B1/en active Active
- 2013-03-13 SG SG10201603059YA patent/SG10201603059YA/en unknown
- 2013-03-13 MX MX2014013633A patent/MX370567B/en active IP Right Grant
- 2013-03-13 EA EA201492052A patent/EA029382B1/en not_active IP Right Cessation
- 2013-03-13 WO PCT/US2013/031053 patent/WO2013169355A1/en active Application Filing
- 2013-03-13 CN CN201810295102.9A patent/CN108498532B/en not_active Expired - Fee Related
- 2013-03-13 LT LTEP13787651.2T patent/LT2846809T/en unknown
- 2013-08-09 US US13/963,526 patent/US8734804B2/en active Active
-
2014
- 2014-11-07 CL CL2014003017A patent/CL2014003017A1/en unknown
- 2014-11-07 MX MX2019009437A patent/MX2019009437A/en unknown
- 2014-11-09 IL IL235593A patent/IL235593B/en active IP Right Grant
-
2015
- 2015-08-25 HK HK15108246.8A patent/HK1207574A1/en unknown
-
2016
- 2016-01-20 US US15/001,773 patent/US20160213706A1/en not_active Abandoned
-
2017
- 2017-03-21 JP JP2017054390A patent/JP6448694B2/en not_active Expired - Fee Related
-
2018
- 2018-03-16 US US15/923,470 patent/US20180296590A1/en not_active Abandoned
- 2018-10-01 JP JP2018186702A patent/JP6726252B2/en not_active Expired - Fee Related
-
2019
- 2019-08-15 US US16/541,660 patent/US11229664B2/en active Active
-
2021
- 2021-01-04 CL CL2021000008A patent/CL2021000008A1/en unknown
- 2021-12-14 US US17/550,942 patent/US20220354882A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201408261UA (en) | Syringe | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201804117XA (en) | Neural cell extracellular vessicles | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201408307VA (en) | Needle guard | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201808539WA (en) | Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201407597XA (en) | Nucleophilic catalysts for oxime linkage | |
| SG11201908052PA (en) | Lipid-based nanoparticles with enhanced stability | |
| SG11201810974QA (en) | Methods and compositions for prostate cancer diagnosis and treatment | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |